GRAILの幹部は、アナリストの見解が分かれ、最近の収益を上回る中、67万ドルの株式を売却しました。 GRAIL executives sold $670K in stock amid mixed analyst views and a recent earnings beat.

2026年3月5日と9日,CEOのロバート・ラグサ,社長のジョシュア・オフマン,CFOのアーロン・フリーディンを含むGRAILの幹部が,別々の取引で合計で約67万ドルの合計12,000株以上を売却した. On March 5 and 9, 2026, several GRAIL executives, including CEO Robert Ragusa, President Joshua Ofman, and CFO Aaron Freidin, sold a combined total of over 12,000 shares, totaling approximately $670,000, in separate transactions. 販売はSECの書類で明らかにされ,ラグサの最大の販売は3月9日に,彼の株式を1.15%削減した. The sales were disclosed in SEC filings, with Ragusa’s largest sale on March 9 reducing his stake by 1.15%. GRAILは2月19日に第4四半期の利益を発表し,予想よりも3.33ドルの損失を上回る2.44ドルの1株の損失を報告し,予測をわずかに上回る43600万ドルの収益を報告した. GRAIL reported fourth-quarter earnings on February 19, posting a loss of $2.44 per share—better than the expected $3.33 loss—with revenue of $43.6 million, slightly above forecasts. 細胞フリーDNAと機械学習を用いたGalleriTMマルチガン早期発見血液検査を開発している同社は,市場規模は194億ドルです. The company, which develops the Galleri™ multi-cancer early detection blood test using cell-free DNA and machine learning, has a market cap of $1.94 billion. 分析者は意見が異なるが,評価は"維持"と目標価格が90.17ドルである. Analysts hold mixed views, with a consensus “hold” rating and a target price of $90.17. 3月10日閲覧. 49.82ドル. ^ 株式は0.41ドル下げ,取引量は平均より下がった. The stock closed at $49.82 on March 10, down $0.41, with trading volume below average.